Retatrutide

Quickstart Highlights

• Once-weekly subcutaneous administration
• Typical start: 0.5–2 mg weekly; gradual increases improve tolerance
• Mix to a practical mg/mL for accurate measuring
• Lyophilised: freeze • After mixing: refrigerate

Product Description

Retatrutide is an investigational peptide-based triple receptor agonist studied for its effects on metabolic regulation in research settings. It targets the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon, enabling researchers to explore coordinated pathways related to appetite signaling, energy balance, and glycemic control.

Overview

How Might Retatrutide Work?

Retatrutide activates GLP-1, GIP, and glucagon receptors implicated in satiety, gastric emptying, glucose homeostasis, and energy expenditure. In research contexts, concurrent receptor activity is explored for potential synergy versus single-pathway agonists.

Protocol Summary

• Goal: weight management & metabolic support
• Schedule: once-weekly subcutaneous injection
• Dose range: typically 0.5–2 mg weekly; advanced protocols may explore up to 12 mg
• Reconstitution options: 2.0 mL (≈ 5 mg/mL) or 1.0 mL (≈ 10 mg/mL)

Dosing & Reconstitution Guide

Reconstitution (choose one)

• Standard: add 2.0 mL bacteriostatic water to a 10 mg vial (≈ 5 mg/mL)
• Advanced: add 1.0 mL bacteriostatic water (≈ 10 mg/mL)
• Run water down vial wall; swirl/roll gently (do not shake). Label vial; refrigerate at 2–8 °C.

Dosing Protocol

Standard (gradual)

• Weeks 1–4: 0.5 mg once weekly
• Weeks 5–8: 1 mg once weekly
• Weeks 9–12: 2 mg once weekly
• Weeks 13–16 (optional): up to 4 mg once weekly

Advanced (aggressive)

• Weeks 1–4: 2 mg once weekly
• Weeks 5–8: 4 mg once weekly
• Weeks 9–12: 8 mg once weekly
• Weeks 13–16 (optional): up to 12 mg once weekly

Administration & cycle

• Route: subcutaneous (Sub-Q)
• Timing: any time of day; keep weekly timing consistent
• Cycle length: 8–12 weeks typical; extend to 16 weeks if continuing

Storage Instructions

• Lyophilised: freeze at −20 °C until reconstitution
• Reconstituted: refrigerate at 2–8 °C; protect from light
• Do not refreeze after thawing

Supplies Needed

• Peptide vials: ~1 vial ≈ 8 weeks low-dose; ~2–3 vials for 12–16 weeks
• Insulin syringes (one per weekly dose)
• Bacteriostatic water (e.g., 30 mL)
• Alcohol swabs

Important Notes

• Increase dose gradually to manage potential side effects
• Track progress and adjust within protocol parameters

Injection Technique

• Clean vial stopper and skin with alcohol swabs
• Insert needle at 45–90° into subcutaneous tissue
• Inject slowly; rotate sites (abdomen, thigh, etc.)

Educational content only.

Research Notes

• Indications of interest: weight-management research, insulin sensitivity, hepatic metabolism, cardiometabolic risk markers.
• Form: typically studied as a peptide candidate under investigation; availability and specifications vary by supplier and jurisdiction.
• Commonly monitored signals in trials: GI effects (nausea, fullness), appetite changes, metabolic labs; comprehensive safety monitoring is standard.
• Data caveats: Ongoing investigation; external validity and long-term outcomes remain active research questions.